Andrew Marciniec

See how food affects your health.

Jane is the cannabis industrys leading technology provider, powering thousands of dispensaries and brands across 39 U.S. states. Jane provides dispensaries and brands a comprehensive suite of digital tools for success – bolstered by proprietary artificial intelligence and machine learning technologies – that span and connect offline and online commerce. Jane empowers businesses to succeed with Ecommerce, Payments, Media, Point of Sale, in-store Kiosks, Jane Gold consumer rewards, MyHigh personalization, and powerful cross-platform Analytics. Jane drives progress in the cannabis industry by building innovative, purpose-driven tools where dispensaries, brands, and consumers win.

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

See how food affects your health.

Blackrock Neurotech is a team of the world’s leading engineers, neuroscientists, and visionaries. Our mission is simple: We want people with neurological disorders to walk, talk, see, hear, and feel again. We’re engineering the next generation of neural implants, including implantable brain-computer interface technology that restores function and independence to individuals with neurological disorders. Join us in changing lives today. Connect with us: Join Our Team | https://bit.ly/3bCsXRv LinkedIn | https://bit.ly/3PfifOL Twitter | https://bit.ly/3PfifOL Instagram | https://bit.ly/3bMaYrW Facebook | https://bit.ly/3JRc2av Clinical Trials | https://bit.ly/3A8QPWm Our site | https://blackrockneurotech.com Additional information: As the world leader in BCI tech, our pioneering neuroscience tools push the boundaries of research and empower innovation across more than 500+ global institutional partners, restoring function in patients suffering from neurological disease (ALS, Alzheimer’s, Parkinson’s), dysfunction (epilepsy, pain, brain trauma), and paralysis disorders. Our systems can be optimized from the ground up to handle even the most challenging applications. Our BCI is the most sophisticated and long-tested human BCI, interfacing with the brain and empowering independence in those with paralysis & other neurological disorders since 2004. In fact, dozens of patients have used our BCI for a collective 30,000+ days to regain freedom through movement and communication. Our first commercial BCI, MoveAgain, received a Breakthrough Designation from the FDA in 2021 and is expected to be commercially available in 2023. Join us in changing lives today.

Jane is the cannabis industrys leading technology provider, powering thousands of dispensaries and brands across 39 U.S. states. Jane provides dispensaries and brands a comprehensive suite of digital tools for success – bolstered by proprietary artificial intelligence and machine learning technologies – that span and connect offline and online commerce. Jane empowers businesses to succeed with Ecommerce, Payments, Media, Point of Sale, in-store Kiosks, Jane Gold consumer rewards, MyHigh personalization, and powerful cross-platform Analytics. Jane drives progress in the cannabis industry by building innovative, purpose-driven tools where dispensaries, brands, and consumers win.

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.